These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 24803587)

  • 1. Neuroprogression in schizophrenia: Pathways underpinning clinical staging and therapeutic corollaries.
    Davis J; Moylan S; Harvey BH; Maes M; Berk M
    Aust N Z J Psychiatry; 2014 Jun; 48(6):512-29. PubMed ID: 24803587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Schizophrenia: linking prenatal infection to cytokines, the tryptophan catabolite (TRYCAT) pathway, NMDA receptor hypofunction, neurodevelopment and neuroprogression.
    Anderson G; Maes M
    Prog Neuropsychopharmacol Biol Psychiatry; 2013 Apr; 42():5-19. PubMed ID: 22800757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions.
    Javitt DC
    Int Rev Neurobiol; 2007; 78():69-108. PubMed ID: 17349858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glutamatergic (N-methyl-D-aspartate receptor) hypofrontality in schizophrenia: too little juice or a miswired brain?
    Marek GJ; Behl B; Bespalov AY; Gross G; Lee Y; Schoemaker H
    Mol Pharmacol; 2010 Mar; 77(3):317-26. PubMed ID: 19933774
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Glutaminergic hypothesis of schizophrenia: clinical research studies with ketamine].
    Mechri A; Saoud M; Khiari G; d'Amato T; Dalery J; Gaha L
    Encephale; 2001; 27(1):53-9. PubMed ID: 11294039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Negative symptoms of schizophrenia: clinical characteristics, pathophysiological substrates, experimental models and prospects for improved treatment.
    Millan MJ; Fone K; Steckler T; Horan WP
    Eur Neuropsychopharmacol; 2014 May; 24(5):645-92. PubMed ID: 24820238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mitochondrial dysfunction in schizophrenia: pathways, mechanisms and implications.
    Rajasekaran A; Venkatasubramanian G; Berk M; Debnath M
    Neurosci Biobehav Rev; 2015 Jan; 48():10-21. PubMed ID: 25446950
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Many Neuroprogressive Actions of Tryptophan Catabolites (TRYCATs) that may be Associated with the Pathophysiology of Neuro-Immune Disorders.
    Morris G; Carvalho AF; Anderson G; Galecki P; Maes M
    Curr Pharm Des; 2016; 22(8):963-77. PubMed ID: 26667000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting of NMDA receptors in new treatments for schizophrenia.
    Hashimoto K
    Expert Opin Ther Targets; 2014 Sep; 18(9):1049-63. PubMed ID: 24965576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Add-on treatment of benzoate for schizophrenia: a randomized, double-blind, placebo-controlled trial of D-amino acid oxidase inhibitor.
    Lane HY; Lin CH; Green MF; Hellemann G; Huang CC; Chen PW; Tun R; Chang YC; Tsai GE
    JAMA Psychiatry; 2013 Dec; 70(12):1267-75. PubMed ID: 24089054
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Evidence on the key role of the metabotrobic glutamatergic receptors in the pathogenesis of schizophrenia: a "breakthrough" in pharmacological treatment].
    Pannese R; Minichino A; Pignatelli M; Delle Chiaie R; Biondi M; Nicoletti F
    Riv Psichiatr; 2012; 47(2):149-69. PubMed ID: 22622251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early brain development disruption from NMDA receptor hypofunction: relevance to schizophrenia.
    du Bois TM; Huang XF
    Brain Res Rev; 2007 Feb; 53(2):260-70. PubMed ID: 17014910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanism of action of antipsychotic drugs: from dopamine D(2) receptor antagonism to glutamate NMDA facilitation.
    Laruelle M; Frankle WG; Narendran R; Kegeles LS; Abi-Dargham A
    Clin Ther; 2005; 27 Suppl A():S16-24. PubMed ID: 16198197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [NMDA-type glutamate receptor and schizophrenia].
    Nishikawa T; Ishiwata S
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2013 Nov; 33(5-6):217-24. PubMed ID: 25069261
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting prefrontal cortical dopamine D1 and N-methyl-D-aspartate receptor interactions in schizophrenia treatment.
    Yang CR; Chen L
    Neuroscientist; 2005 Oct; 11(5):452-70. PubMed ID: 16151046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The neuropathology of schizophrenia.
    Bachus SE; Kleinman JE
    J Clin Psychiatry; 1996; 57 Suppl 11():72-83. PubMed ID: 8941174
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New perspectives on biological treatment of schizophrenia.
    Lingjaerde O
    Acta Psychiatr Scand Suppl; 1994; 384():102-7. PubMed ID: 7879631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glutamatergic mechanisms in schizophrenia.
    Tsai G; Coyle JT
    Annu Rev Pharmacol Toxicol; 2002; 42():165-79. PubMed ID: 11807169
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuroprogression in schizophrenia: pathways and underpinning clinical staging and therapeutic corollaries.
    Stein K; Broome MR
    Aust N Z J Psychiatry; 2015 Feb; 49(2):183-4. PubMed ID: 25332461
    [No Abstract]   [Full Text] [Related]  

  • 20. Significance of dysfunctional glutamatergic transmission for the development of psychotic symptoms.
    Pietraszek M
    Pol J Pharmacol; 2003; 55(2):133-54. PubMed ID: 12926541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.